RxSight
RXST
57 hedge funds and large institutions have $121M invested in RxSight in 2022 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 24 increasing their positions, 13 reducing their positions, and 6 closing their positions.
1,846% more call options, than puts
Call options by funds: $253K | Put options by funds: $13K
85% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 13
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
11% more capital invested
Capital invested by funds: $109M → $121M (+$12M)
8% more funds holding
Funds holding: 53 → 57 (+4)
1.63% more ownership
Funds ownership: 32.97% → 34.6% (+1.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
+$7.88M |
| 2 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$618K |
| 3 |
ACM
Altium Capital Management
New York
|
+$615K |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$581K |
| 5 |
BlackRock
New York
|
+$487K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BM
Bridger Management
New York
|
-$2.66M |
| 2 |
SC
Sessa Capital
New York
|
-$1.63M |
| 3 |
Millennium Management
New York
|
-$1.1M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$188K |
| 5 |
SC
Saturna Capital
Bellingham,
Washington
|
-$173K |
RXST Hedge Fund Activity: Q4 2022 in Review
57 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in RxSight (RXST) for Q4 2022, worth a combined $121M — up 11% from $109M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new RXST positions and 6 closed out — a net gain of 5 holders — while 24 added to existing stakes and 13 trimmed.
The largest buyer was Next Century Growth Investors, opening a new position worth an estimated $7.88M. The largest seller was Bridger Management, exiting entirely with an estimated $2.66M sold.
- 57 institutional investors held RxSight (RXST) as of Q4 2022, up from 53 in Q3 2022.
- Funds reported $121M of RxSight stock for Q4 2022, up 11% quarter-over-quarter.
- 11 funds opened new RxSight positions in Q4 2022 and 6 closed out, a net change of +5 holders.
- The largest RxSight buyer in Q4 2022 was Next Century Growth Investors, an estimated $7.88M added.
- The largest RxSight seller in Q4 2022 was Bridger Management, an estimated $2.66M sold.
Based on aggregated 13F filings for Q4 2022.